Skip to main content
. 2014 Sep 14;20(34):12026–12030. doi: 10.3748/wjg.v20.i34.12026

Table 1.

Possible association between interleukin 28B genetic polymorphism and the effect of interferon-α and/or pegylated interferon-α, or spontaneous hepatitis B e antigen and/or hepatitis B surface antigen clearance in hepatitis B virus infection

No. Year Ref. Targeted SNPs Subject settings HBe Result Comments
1 2010 Martin et al[20] rs12979860 226 HBV persistence, 384 HBV recovery ND Negative C/C genotype of rs12979860 was not associated with HBV recovery (OR = 0.99)
2 2011 Li et al[21] rs12979860, rs12980275, rs8099917 203 chronic HBV infection, 203 self-limited HBV infection, 203 individuals negative for all HBV seromarkers (Chinese Han population) ND Negative
3 2011 Tseng et al[22] IL28B regions 115 HBeAg-positive chronic hepatitis B patients Positive Negative
4 2012 Sonneveld et al[23] rs12980275, rs12979860 205 HBeAg-positive patients who were treated with PEG-IFN (Europeans and Asians) Positive Positive IL28B genotype was significantly associated with HBeAg seroconversion at the end of treatment (P < 0.001, OR = 3.16), during long-term follow up (HR = 2.14), or with HBsAg seroclearance (HR = 3.47)
5 2012 Wu et al[24] rs8099917 512 HBeAg positive chronic hepatitis B patients (Han Chinese) were treated with pegylated interferon a-2a ± nucleoside analogues Positive Positive The frequency of G allele of rs8099917 was significantly higher in the response group than in the non-response group (8.3% vs 3.9%, P = 0.003, OR = 0.44, 95%CI: 0.25-0.79). The genotype distributions of this SNP also differed significantly between the two groups (P = 0.003)
6 2012 de Niet et al[25] rs12979860 95 chronic hepatitis B patients who were treated with PEG-IFN and adefovir for 1 yr and who had 15% HBsAg loss (overall) Positive and negative Negative
7 2012 Peng et al[26] rs12979860 651 HBV persistent infection (387 with liver cirrhosis, 264 without cirrhosis), 226 healthy individuals who recovered from HBV infection ND Negative No association with clearance of HBsAg, HBeAg, HBV DNA level, apparent hepatitis onset and liver cirrhosis (P > 0.05)
8 2013 Lampertico et al[31] rs12979860 101 HBeAg-negative patients (92% genotype D) with compensated chronic hepatitis B (84% males, 42% with cirrhosis) Negative Positive The rate of serum HBsAg clearance was 29% in CC (major homo) compared to 13% in non-CC (hetero or minor homo) genotype carriers (P = 0.039)
9 2013 Seto et al[32] IL28B (rs12979860, rs8099917) 203 chronic hepatitis B patients achieving spontaneous HBsAg seroclearance with 203 age- and sex-matched chronic hepatitis B patients without HBsAg seroclearance (control) Negative Positive IL28B haplotype block CG was associated with HBsAg seroclearance (OR = 10.5, P = 0.026)
10 2013 Holmes et al[33] rs12979860 96 patients (88% were Asian, 62% were HBeAg positive and 13% were METAVIR stage F3-4). The majority (84%) of patients carried the CC IL28B genotype (major homo) Positive and negative Negative
11 2013 Lee et al[34] rs8099917, rs12979860, rs12980275 404 spontaneously recovered patients, 313 chronic hepatitis B patients, 305 liver cirrhosis patients and 417 hepatocellular carcinoma patients ND Negative

Studies are chronologically numbered. HBV: Hepatitis B virus; ND: Not determined or not described; IL: Interleukin; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; PEG-IFN: Pegylated interferon-α.